卒中后癫痫发作患者的结局:系统综述与Meta分析
该系统综述与Meta分析检索1951年至2023年1月30日的观察性研究,纳入71篇文献共20 110例卒中后癫痫发作(PSS)患者和1 166 085例无PSS患者。结果显示PSS与死亡风险(OR 2.1)、不良功能结局(OR 2.2)、残疾加重(SMD 0.6)及痴呆风险增加(OR 3.1)相关。早期发作与死亡相关,而晚期发作与死亡无显著相关;早期和晚期发作均与不良结局相关。
要点
- PSS患者死亡风险为无PSS患者的2.1倍(OR 2.1,95%CI 1.8-2.4)。
- PSS患者不良功能结局风险为无PSS患者的2.2倍(OR 2.2,95%CI 1.8-2.8)。
- 早期发作与死亡相关(OR 2.4,95%CI 1.9-2.9),晚期发作与死亡无显著相关(OR 1.2,95%CI 0.8-2.0)。
核心结论
- 该系统综述与Meta分析提示,PSS与卒中患者死亡率和严重残疾显著增加相关,阐明这些关联是临床和研究的高度优先事项,预防癫痫发作的干预试验可能有必要。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE、Embase、PsycInfo、Cochrane、LILACS、LIPECS和Web of Science从1951年至2023年1月30日的文献,纳入报告PSS结局的观察性研究,共71篇 eligible 文章,包括20 110例PSS患者和1 166 085例无PSS患者。
主要发现
- PSS患者中1967例(9.8%)为早期发作,10 605例(52.7%)为晚期发作。
- 与无PSS患者相比,PSS与死亡风险(OR 2.1,95%CI 1.8-2.4)、不良功能结局(OR 2.2,95%CI 1.8-2.8)、残疾加重(SMD 0.6,95%CI 0.4-0.7)和痴呆风险增加(OR 3.1,95%CI 1.3-7.7)相关。
- 亚组分析中,早期发作与死亡相关(OR 2.4,95%CI 1.9-2.9),晚期发作与死亡无显著相关(OR 1.2,95%CI 0.8-2.0);缺血性和出血性卒中亚型均与死亡相关(OR 2.2,95%CI 1.8-2.7 vs OR 1.4,95%CI 1.0-1.8)。
- 早期和晚期发作均与不良结局相关(OR 2.4,95%CI 1.6-3.4 vs OR 2.7,95%CI 1.8-4.1),卒中亚型亦与不良结局相关(OR 2.6,95%CI 1.9-3.7 vs OR 1.9,95%CI 1.0-3.6)。
- 偏倚风险:5项研究(7.0%)为高,35项(49.3%)为中等,31项(43.7%)为低。
临床怎么用
- 原文结论未据此给出具体临床推荐,仅指出预防癫痫发作的干预试验可能有必要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Published data about the impact of poststroke seizures (PSSs) on the outcomes of patients with stroke are inconsistent and have not been systematically evaluated, to the authors' knowledge. OBJECTIVE: To investigate outcomes in people with PSS compared with people without PSS. DATA SOURCES: MEDLINE, Embase, PsycInfo, Cochrane, LILACS, LIPECS, and Web of Science, with years searched from 1951 to January 30, 2023. STUDY SELECTION: Observational studies that reported PSS outcomes. DATA EXTRACTION AND SYNTHESIS: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist was used for abstracting data, and the Joanna Briggs Institute tool was used for risk-of-bias assessment. Data were reported as odds ratio (OR) and standardized mean difference (SMD) with a 95% CI using a random-effects meta-analysis. Publication bias was assessed using funnel plots and the Egger test. Outlier and meta-regression analyses were performed to explore the source of heterogeneity. Data were analyzed from November 2022 to January 2023. MAIN OUTCOMES AND MEASURES: Measured outcomes were mortality, poor functional outcome (modified Rankin scale [mRS] score 3-6), disability (mean mRS score), recurrent stroke, and dementia at patient follow-up. RESULTS: The search yielded 71 eligible articles, including 20 110 patients with PSS and 1 166 085 patients without PSS. Of the participants with PSS, 1967 (9.8%) had early seizures, and 10 605 (52.7%) had late seizures. The risk of bias was high in 5 studies (7.0%), moderate in 35 (49.3%), and low in 31 (43.7%). PSSs were associated with mortality risk (OR, 2.1; 95% CI, 1.8-2.4), poor functional outcome (OR, 2.2; 95% CI, 1.8-2.8), greater disability (SMD, 0.6; 95% CI, 0.4-0.7), and increased dementia risk (OR, 3.1; 95% CI, 1.3-7.7) compared with patients without PSS. In subgroup analyses, early seizures but not late seizures were associated with mortality (OR, 2.4; 95% CI, 1.9-2.9 vs OR, 1.2; 95% CI, 0.8-2.0) and both ischemic and hemorrhagic stroke subtypes were associated with mortality (OR, 2.2; 95% CI, 1.8-2.7 vs OR, 1.4; 95% CI, 1.0-1.8). In addition, early and late seizures (OR, 2.4; 95% CI, 1.6-3.4 vs OR, 2.7; 95% CI, 1.8-4.1) and stroke subtypes were associated with poor outcomes (OR, 2.6; 95% CI, 1.9-3.7 vs OR, 1.9; 95% CI, 1.0-3.6). CONCLUSIONS AND RELEVANCE: Results of this systematic review and meta-analysis suggest that PSSs were associated with significantly increased mortality and severe disability in patients with history of stroke. Unraveling these associations is a high clinical and research priority. Trials of interventions to prevent seizures may be warranted.
引用
- Misra S, Kasner SE, Dawson J, et al. Outcomes in Patients With Poststroke Seizures: A Systematic Review and Meta-Analysis. JAMA Neurol. 2023. PMID: 37721736. doi:10.1001/jamaneurol.2023.3240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。